Detection bias in French Polynesia seems unlikely because measurement of head circumference is part of routine ultrasound examination during pregnancy, and any serious abnormality missed during pregnancy should be detected after birth. Besides, the prevalence of microcephaly in the 4 months following the Zika virus outbreak in French Polynesia (47 cases [95% CI 20-100] per 10 000 births) was remarkably consistent with the prevalence reported in the northeast region in Brazil (64 cases [61-67] per 10 000 births), which has been the most affected by Zika virus (figure). 3 Prevalence for Brazil was calculated under the assumption that 32% of suspected microcephaly cases will eventually be confi rmed, which is consistent with data available as of June 18, 2016, 4 although uncertainty about this proportion remains substantial. 5 These results are consistent with our model that predicts about 50 cases per 10 000 births in the worst affected pregnancy cohort in French Polynesia.
Another possibility could be that we overestimated the proportion of women of childbearing age infected by Zika virus in French Polynesia, since we assumed that this proportion would be similar to the 66% of school-age children who had positive serological tests after the epidemic. However, although we cannot rule out the possibility that seroprevalence varies with age, the fourtimes difference between adults and children that is necessary to explain the discrepancy seems unlikely (ie, a 16% attack rate would be needed in women of childbearing age).
Diff erences in case defi nitions might partly explain the discrepancies. Microcephaly cases in our study all had serious brain abnormalities. 6 Overall, we agree with Freitas and colleagues that comparison of the two studies supports the hypothesis that the risk of microcephaly might increase with the presence of symptoms in the infected mother. Since most infections are thought to be asymptomatic, a substantial proportion of Zika virus-related microcephaly could still come from women who did not have any symptoms. Follow-up of pregnant women with and without symptoms will be essential to better characterise this relation. 
Haemodialysis is a major risk factor for infective endocarditis
In their Seminar (Feb 27, p 882), Thomas Cahill and Bernard Prendergast 1 point out that the prevalence of health-care-acquired infective endocarditis has increased in the past decades, accounting for more than 25% of cases at present. However, the epidemiological concept of "health-care-acquired" does not highlight at-risk populations. In particular, the authors briefl y mention but regrettably omit haemodialysis as a risk factor for infective endocarditis. Indeed, in a 2012 population-based observational study done in France, 2 ten www.thelancet.com Vol 388 July 23, 2016 trial. 2 The authors assert that most of the outcomes we considered non-prespecifi ed are in fact prespecifi ed in a protocol that was submitted to The Lancet after trial commencement but not published, and that a summary protocol was subsequently published that did not contain all prespecified outcomes.
This argument implies that the outcomes specifi ed in the protocol are diff erent from those in the registry entry. The authors claim that "trial registries often do not request or have space for sufficient detail about secondary outcomes". We disagree. Trial registries were specifically set up as a platform to prespecify primary and secondary outcomes, and there is ample space for all three components of each outcome: the variable, method of measurement, and timepoint of measurement.
Their response also raises the issue of outcomes being prespecified in protocols that are inaccessible to the public. On this issue, we agree with Davidson and colleagues: protocols should be published in full with the main trial publication, including details of prespecifi ed outcomes and any changes after trial commence ment. We would be interested to hear the editors' reasons for not publishing this protocol and their views on inadequate specifi cation of outcomes in trial registry entries.
All raw data from the COMPare project are shared openly online. These data have been scrutinised by several well resourced teams of trialists and journalists. So far, we have found two errors in our coding out of 657 misreported outcomes identifi ed. The apnoea outcomes for the GAS trial are declared in the trial publication as "reported elsewhere", 3 which we missed in our original analysis. We regard this as correct outcome reporting and have changed the coding of this outcome to "correctly reported" in our assessment sheet. (8·2%) of 122 health-care-associated infective endocarditis cases occurred in patients who were undergoing haemodialysis, compared with 29 (5·8% of total infective endocarditis cases) in intravenous drug users, a risk factor mentioned six times in the Seminar. The risk of infective endocarditis in patients undergoing haemodialysis is 17·8 times higher than that in the general population, with more than 50% of cases caused by Staphylococcus aureus and an in-hospital mortality of roughly 50%. 3 Infective endocarditis in the setting of haemodialysis has been strongly associated with vascular access infection, both in patients with catheters and in those with arteriovenous fi stulas. 2, 4 The risk of infective endocarditis is so high in patients undergoing haemodialysis that a 2014 systematic review 5 concluded that not being dependent on haemodialysis is one of the fi ve characteristics associated with a low risk of infective endocarditis in patients with S aureus bacteraemia, in whom transoesophageal echocardiography can be safely avoided.
In conclusion, haemodialysis should be listed as a major risk factor for infective endocarditis, and any sign (eg, febrile stroke) in patients undergoing haemodialysis should raise a high degree of suspicion for infective endocarditis. MJ reports grants from Amgen and Fresenius, payment to his hospital/institution for work on a randomised controlled trial from Amgen, and research grants paid to his hospital/institution from Baxter, Amgen, Fresenius, Janssen-Cilag, and Roche, outside the submitted work. LL declares no competing interests.
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